Envoy Medical EBIT

The latest EBIT for COCH is $-24M as of March 2026. That compares with $-19M in the prior-year period — down 25.8% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Envoy Medical's historical trend and sector peers before judging valuation or financial health.

Over the past year, COCH's EBIT moved from $-19M to $-24M — a 25.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Envoy Medical's operating scale or balance-sheet position.

Against its sector companies, COCH currently prints $-24M for EBIT, while the sector average sits near $-63M. That is roughly 62.1% above the sector mean. Large gaps often invite a closer look at Envoy Medical's growth, margins, and balance sheet.

A EBIT figure of $-24M for COCH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting COCH's EBIT ($-24M), review year-over-year change from $-19M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.